Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Doctor who cured ‘Berlin patient’ of HIV: ‘We knew we were doing something very special’

Dr. Gero Hütter and Timothy Ray Brown speak about the transplant that forever linked them in medical history.

Published
02 March 2015
From
Fred Hutch News
Tenofovir, boosted atazanavir and boosted lopinavir are associated with cumulative risk of developing chronic kidney disease

Three antiretroviral drugs are associated with a slowly increasing rate of chronic kidney disease over time, the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in

Published
27 February 2015
By
Gus Cairns
Inflammation Persists Despite Very Early HIV Treatment

Biomarkers of inflammation increase during acute HIV infection and remain elevated despite early suppressive antiretroviral therapy, according to a study presented at CROI 2015, in Seattle, Washington.

Published
27 February 2015
From
The Body Pro
Tenofovir alafenamide equally effective but safer for kidneys and bones than current formulation

Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil

Published
27 February 2015
By
Liz Highleyman
48-week analysis of investigational HIV-1 attachment inhibitor paves way for Phase III trial initiation

Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients. Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells. Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells PRINCETON, N.J., February 25, 2015--Bristol-Myers Squibb Company (NYSE:BMY) today announced data...

Published
26 February 2015
From
Bristol Myers Squibb press release
HIV maturation inhibitor BMS-955176 looks promising in early study

A second-generation HIV maturation inhibitor, BMS-955176, demonstrated good safety and high potency, including activity against viral strains that were not susceptible to an earlier drug in this class,

Published
26 February 2015
By
Liz Highleyman
Starting HIV treatment at CD4 count above 500 reduces the risk of serious illness and death by 44%, African Temprano trial shows

Starting HIV treatment at a CD4 cell count above 500 reduced the risk of serious illness including tuberculosis (TB), and death, by 44% when compared to starting

Published
26 February 2015
By
Keith Alcorn
Week-on, weekend-off treatment controls viral load in young people

Taking an efavirenz-based antiretroviral regimen during the week and taking no medication on two days over the weekend was just as effective as daily treatment in controlling

Published
25 February 2015
By
Keith Alcorn
Disappointing result for tenofovir-gel microbicide shows that young women still lack HIV prevention methods they can use

Among some highly promising results from HIV prevention studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, today, there was

Published
25 February 2015
By
Gus Cairns
7-country study shows triple-drug combination superior for preventing infant HIV infection

Implementing the World Health Organization (WHO) recommendation of three-drug antiretroviral treatment during pregnancy leads to a significantly lower rate of mother-to-child HIV transmission, a 7-country randomised study has

Published
25 February 2015
By
Keith Alcorn

Filter by country